ITP is the most common cause of isolated thrombocytopenia, an acquired autoimmune disorder in which autoantibodies target platelets for premature destruction, primarily in the spleen and liver. [1-2] It is a diagnosis of exclusion — defined as a platelet count <100 × 10³/μL with no other identifiable cause of thrombocytopenia. [1] Incidence is 2–5 per 100,000 person-years, with peaks at ages 20–30 (slight female predominance) and >60 years (equal sex distribution). [1][3]
1. History
- Onset and timing: Acute vs. gradual onset; in children, often sudden and self-limited; in adults, typically insidious and chronic (up to 70% develop chronic ITP) [1][4]
- Bleeding symptoms: Easy bruising, petechiae, purpura, epistaxis, gum bleeding, menorrhagia, hematuria, GI bleeding [4-5]
- Severity and progression: Quantify bleeding frequency, volume, and impact on daily activities
- Preceding illness: Recent viral URI (especially in children), vaccination history (MMR, varicella, COVID-19, influenza) [4][6]
- Medication review: New medications within 3–10 days (quinine/quinidine, acetaminophen, carbamazepine, rifampicin, vancomycin, abciximab, TMP-SMX); OTC drugs, herbals, supplements [1][7]
- Anticoagulant/antiplatelet use: Increases bleeding risk at any platelet level [8]
- Important negatives: Absence of fever, weight loss, night sweats, bone pain, joint symptoms, lymphadenopathy, hepatosplenomegaly — these suggest alternative diagnoses [1]
2. Alarm Features
- Platelet count <10 × 10³/μL — high risk of spontaneous, life-threatening bleeding [2]
- Intracranial hemorrhage (ICH) — rare but the most feared complication; presents with severe headache, altered mental status, focal neurologic deficits [4]
- Active serious bleeding: GI hemorrhage, hemodynamic instability, hematuria with clots
- Wet purpura (oral blood blisters) — marker of more severe mucosal bleeding risk [8]
- Neurologic symptoms — must rule out TTP (schistocytes, elevated LDH, low ADAMTS13) [1][9]
- Fever + thrombocytopenia — consider TTP/HUS, DIC, sepsis [6]
- Concurrent anemia with schistocytes — suggests thrombotic microangiopathy, not ITP [6][9]
3. Medications
First-line treatments
- Corticosteroids: Prednisone 1–2 mg/kg/day for 1–2 weeks then taper, or dexamethasone 40 mg/day × 4 days (up to 4 cycles); ~80% initial response rate, but >50% relapse on taper [1][3]
- IVIG: 1 g/kg × 1–2 days; raises platelets within 1–4 days in ~80% of patients; effect transient (1–2 weeks); indicated for active serious bleeding or platelets <10 × 10³/μL [1]
- Tranexamic acid: Adjunct for mucosal bleeding [10]
Second-line treatments
- TPO-receptor agonists: Romiplostim (1–10 μg/kg SC weekly), eltrombopag (25–75 mg PO daily), avatrombopag (5–40 mg PO daily) — for ITP refractory to corticosteroids [1][11]
- Rituximab: 375 mg/m² IV weekly × 4 weeks; sustained response in ~60% at 6 months, ~30% at 2 years [1]
- Fostamatinib: 100–150 mg PO BID for chronic ITP refractory to prior treatment [1][11]
- Splenectomy: Reserved for chronic ITP (>12 months) refractory to medical therapy [1]
Medications to AVOID in ITP
- NSAIDs and aspirin — impair platelet function and increase bleeding risk
- Anticoagulants — discontinue during active bleeding; reintroduce only when platelets >50 × 10³/μL [1]
- Drugs known to cause thrombocytopenia: Quinine, quinidine, heparin, carbamazepine, vancomycin, rifampicin, TMP-SMX [1][7]
Cautions with treatment
- Prolonged corticosteroid use should be avoided (diabetes, osteoporosis, infection risk) [1]
- Eltrombopag: take 4 hours after and 2 hours before calcium/iron-containing foods; monitor LFTs [1]
- Rituximab: screen for HBV before use; risk of PML (very rare) [1]
4. Diet
- No specific dietary triggers for ITP
- Avoid alcohol — can independently suppress platelet production and worsen thrombocytopenia (3–43% of alcohol-dependent individuals develop thrombocytopenia) [6]
- Eltrombopag interaction: Must be taken on an empty stomach; avoid dairy, calcium, iron, and antacids within the specified window [1]
- Adequate hydration and nutrition to support marrow function
5. Review of Systems
- Skin: Petechiae, purpura, ecchymoses, new or worsening bruising
- HEENT: Epistaxis, gum bleeding, oral blood blisters (wet purpura), visual changes
- GI: Hematemesis, melena, hematochezia, abdominal pain
- GU: Hematuria, menorrhagia
- Neuro: Headache, confusion, focal deficits (red flag for ICH or TTP)
- Constitutional: Fever, weight loss, night sweats (suggest malignancy, infection, or TTP — atypical for primary ITP) [1][6]
- MSK: Arthralgias, joint swelling (suggest SLE or other autoimmune disease) [1]
- Infectious: Recent illness, travel history, high-risk behaviors (HIV, hepatitis) [1][6]
6. Collateral History and Family History
- Family history of bleeding disorders or thrombocytopenia — consider congenital thrombocytopenias (Bernard-Soulier, MYH9-related disorders) [1]
- Family history of autoimmune disease — SLE, rheumatoid arthritis, thyroid disease increases likelihood of secondary ITP [1]
- Social context: Ability to recognize bleeding symptoms, access to emergency care, medication compliance, alcohol use [6][12]
- Collateral from prior labs: Obtain previous CBC results to distinguish acute vs. chronic thrombocytopenia [6]
7. Risk Factors
- Age: Bimodal — young adults (20–30) and older adults (>60) [1]
- Sex: Slight female predominance in younger patients; equal in older adults [1]
- Autoimmune comorbidities: SLE, rheumatoid arthritis, antiphospholipid syndrome, thyroid disease [1]
- Infections: HIV, HCV, HBV, CMV, EBV, H. pylori — all associated with secondary ITP [1]
- Lymphoproliferative disorders: CLL, Hodgkin lymphoma [1]
- Immunodeficiency syndromes: CVID, autoimmune lymphoproliferative syndrome [1]
- Recent vaccination (rare trigger) [6]
- Pregnancy — must distinguish from gestational thrombocytopenia and preeclampsia/HELLP [13]
8. Differential Diagnosis
Dangerous cannot-miss diagnoses
- Thrombotic thrombocytopenic purpura (TTP): Neurologic symptoms, MAHA (schistocytes), elevated LDH, low ADAMTS13 (<10%) [1][9]
- Hemolytic uremic syndrome (HUS): Renal failure predominant, MAHA [1]
- Disseminated intravascular coagulation (DIC): Elevated PT/PTT, low fibrinogen, elevated D-dimer [6]
- Heparin-induced thrombocytopenia (HIT): Thrombosis + heparin exposure [1]
- Acute leukemia/MDS: Other cytopenias, blasts on smear [1]
Common mimics
- Pseudothrombocytopenia: EDTA-induced platelet clumping; repeat in citrate tube [1]
- Drug-induced thrombocytopenia: Resolves 7–10 days after drug withdrawal [6]
- Gestational thrombocytopenia: Mild (usually >70 × 10³/μL), third trimester, resolves postpartum [13]
- Liver disease/hypersplenism: Hepatosplenomegaly, abnormal LFTs [1]
- Evans syndrome: ITP + DAT-positive hemolytic anemia [1]
9. Past Medical History
- Prior episodes of thrombocytopenia or ITP (relapse vs. chronic)
- Autoimmune diseases: SLE, RA, antiphospholipid syndrome, thyroid disease [1]
- Chronic infections: HIV, hepatitis B/C [1]
- Lymphoproliferative disorders [1]
- Splenectomy history — affects treatment options
- Prior response to corticosteroids or IVIG — guides current management
- Surgical history: Bariatric surgery (nutritional deficiencies), valve replacement (mechanical destruction) [6]
10. Physical Exam
Vital signs: Tachycardia and hypotension suggest active hemorrhage
Focused exam
- Skin: Petechiae (dependent areas, pressure points), purpura, ecchymoses — quantify size and distribution [6]
- Oral cavity: Wet purpura (hemorrhagic bullae on buccal mucosa), gum bleeding — indicates higher bleeding risk [5][8]
- Fundoscopic exam: Retinal hemorrhages (concern for ICH risk)
- Lymph nodes: Lymphadenopathy suggests lymphoproliferative disorder, infection, or SLE — atypical for primary ITP [1][6]
- Abdomen: Hepatosplenomegaly — suggests liver disease, lymphoma, or portal hypertension; spleen is NOT typically enlarged in primary ITP [1][6]
- Neurologic: Mental status, focal deficits — if present, urgently evaluate for ICH or TTP [6]
Expected findings in ITP: Isolated mucocutaneous bleeding signs with an otherwise normal exam. Any systemic findings (lymphadenopathy, splenomegaly, fever) should prompt evaluation for secondary causes. [1]
11. Lab Studies
Initial workup
- CBC with differential: Isolated thrombocytopenia; other cell lines normal [1]
- Peripheral blood smear: Reduced platelets, may show large platelets (not pathognomonic); no schistocytes, blasts, or dysplastic changes [1]
- Reticulocyte count: Normal (unless concurrent bleeding)
- Coagulation studies (PT/INR, PTT, fibrinogen): Normal in ITP; abnormal suggests DIC [6]
To rule out secondary causes
- Hemolysis panel: LDH, haptoglobin, indirect bilirubin, DAT (Coombs test) — to exclude TTP, Evans syndrome [1][6]
- Viral serologies: HIV, HBV, HCV [1][6]
- H. pylori testing: Stool antigen or breath test [1][6]
- Renal and hepatic function tests [6]
- ANA, antiphospholipid antibodies — if autoimmune disease suspected [1]
- Immunoglobulin levels — if immunodeficiency suspected [1]
- Thyroid function tests — when clinically indicated [6]
Not routinely recommended
- Antiplatelet antibody testing: Detected in only 50–60% of ITP patients; not recommended in diagnostic workup [1]
- Bone marrow biopsy: Not diagnostic; reserved for atypical presentations, other cytopenias, or treatment-refractory cases [1]
12. Imaging
- Not routinely required for diagnosis of primary ITP
- Abdominal ultrasound: Assess for hepatosplenomegaly if suspected on exam; splenomegaly suggests alternative diagnosis (portal hypertension, lymphoma) [1]
- CT chest/abdomen/pelvis: Only if lymphoproliferative disorder or solid malignancy suspected (weight loss, night sweats, lymphadenopathy) [1]
- CT head (non-contrast): Urgently indicated if any neurologic symptoms to rule out intracranial hemorrhage [4]
13. Special Tests
- Immature platelet fraction (IPF%) or reticulated platelets: Elevated in ITP (increased platelet turnover); helps differentiate from hypoproductive causes [14]
- Plasma thrombopoietin (TPO) levels: Normal or slightly increased in ITP; markedly elevated in aplastic anemia [14]
- ADAMTS13 activity: Order if TTP is in the differential (thrombocytopenia + MAHA); <10% confirms TTP [9]
- Flow cytometry: If concern for leukemia or lymphoproliferative disorder [1]
- Bone marrow aspirate/biopsy: Only for atypical features, other cytopenias, age >60 (to exclude MDS), or treatment failure [1]
The following figure illustrates the evaluation algorithm for thrombocytopenia:
14. ECG
- Not routinely indicated for ITP itself
- Consider ECG if:
- Hemodynamically significant bleeding (tachycardia, hypotension)
- Concurrent chest pain or dyspnea (pericardial effusion from autoimmune disease)
- Evaluating for TTP (cardiac ischemia can occur) [9]
- No ITP-specific ECG patterns
15. Assessment
Classification by duration: [15]
- Newly diagnosed: <3 months from diagnosis
- Persistent: 3–12 months
- Chronic: >12 months
Severity stratification
- Platelets ≥30 × 10³/μL, no bleeding → observation may be appropriate [8]
- Platelets <30 × 10³/μL → corticosteroids recommended regardless of bleeding [3][8]
- Platelets <20 × 10³/μL → consider hospitalization for newly diagnosed patients [2][12]
- Platelets <10 × 10³/μL → high risk of spontaneous bleeding; add IVIG [1-2]
Key clinical pearls
- Only ~5% of ITP patients present with severe bleeding, but ~15% develop bleeding requiring hospitalization within 5 years [1]
- VTE risk is twice that of the general population despite low platelets [1]
- Fatigue and impaired quality of life are common even without bleeding [1]
- Chronic ITP develops in up to 70% of adults; spontaneous remission can occur years later [1]
16. Treatment Plan
The following figure illustrates the mechanism of action of ITP therapies:
Active serious bleeding (emergency)
Per the McMaster ITP Emergency Management Guideline (2026), a critical bleed warrants combined use of: [10]
- Platelet transfusions (transient effect, use with other agents)
- High-dose corticosteroids (methylprednisolone 1 g IV or dexamethasone 40 mg IV)
- IVIG 1 g/kg (repeat day 2 if needed)
- Tranexamic acid (1 g IV or 1.3 g PO TID)
- TPO-receptor agonist (romiplostim or eltrombopag)
- Discontinue all anticoagulants and antiplatelet agents [1]
- Conditional recommendation for urgent splenectomy if all else fails; conditional recommendation against recombinant factor VIIa (thrombosis risk) [10]
Non-bleeding / minor bleeding
- Platelets ≥30 × 10³/μL, asymptomatic or minor bleeding: Observation with close follow-up [8]
- Platelets <30 × 10³/μL: Corticosteroids — prednisone 1–2 mg/kg/day × 1–2 weeks then taper, OR dexamethasone 40 mg × 4 days [1]
- Add IVIG if rapid platelet rise needed (pre-procedure, severe thrombocytopenia <10 × 10³/μL) [1]
Refractory/relapsed ITP
- TPO-receptor agonists (romiplostim, eltrombopag, avatrombopag) — preferred for sustained response [1][11]
- Rituximab — alternative; slower onset but durable in some patients [1]
- Fostamatinib — for chronic ITP after insufficient response to prior treatment [11]
- Splenectomy — defer until >12 months from diagnosis; reserved for medical treatment failure [1][6]
17. Disposition
Admission criteria (per ASH 2019 Guidelines): [8][12]
- Newly diagnosed ITP with platelets <20 × 10³/μL — admission suggested even if asymptomatic or with minor mucocutaneous bleeding
- Active significant bleeding at any platelet count
- Diagnostic uncertainty
- Significant comorbidities increasing bleeding risk
- Social concerns or inability to ensure follow-up
Outpatient management appropriate for: [8][12]
- Platelets ≥20 × 10³/μL with no or minor bleeding
- Established ITP (known diagnosis) with platelets <20 × 10³/μL if asymptomatic and previously responsive to rescue agents
- Reliable follow-up with hematology within 24–72 hours ensured [12]
Observation (no treatment)
Hematology consultation
- All newly diagnosed ITP patients should have hematology follow-up within 24–72 hours [12]
- Urgent consultation for refractory disease, diagnostic uncertainty, or consideration of splenectomy
18. Follow-Up / Return Precautions
Follow-up timing
- Hematology follow-up within 24–72 hours of new diagnosis or relapse [12]
- Repeat CBC within 1–2 weeks after initiating treatment to assess response
- If on corticosteroids: monitor glucose, blood pressure, and taper schedule
- If on TPO-RAs: regular CBC monitoring; watch for rebound thrombocytopenia on discontinuation [1]
- If on eltrombopag: LFTs at baseline and regularly during treatment [1]
Return precautions — instruct patients to seek immediate care for:
- New or worsening bleeding (nosebleeds not stopping with pressure, blood in urine/stool, heavy menstrual bleeding)
- Severe headache, vision changes, confusion, or weakness — concern for intracranial hemorrhage [4]
- Oral blood blisters (wet purpura)
- Dizziness, lightheadedness, or syncope (hemodynamic compromise)
- New bruising significantly worse than baseline
Patient counseling
- Avoid contact sports and activities with high injury risk while severely thrombocytopenic
- Avoid aspirin, NSAIDs, and other platelet-impairing medications
- Avoid alcohol
- Wear a medical alert bracelet if chronically thrombocytopenic
- In children, most cases resolve spontaneously within weeks to months; in adults, chronic disease is common but manageable [1][4][15]
References
1. Immune Thrombocytopenia. — Cooper N, Ghanima W. The New England Journal of Medicine. 2019.
2. Hematologic Emergencies: Recognition and Initial Management. — Jones DE, Walker JJ, Abellada AMP. American Family Physician. 2024.
3. Efficacy and Safety of Treatments in Newly Diagnosed Adult Primary Immune Thrombocytopenia: A Systematic Review and Network Meta-Analysis. — Wang Y, Sheng L, Han F, et al. EClinicalMedicine. 2023.
4. Immune thrombocytopenia. — National Library of Medicine (MedlinePlus) 2017.
5. Early Diagnosis and Tailored Treatment in Atypical Idiopathic Thrombocytopenic Purpura: A CARE Compliant Case Report. — Patel T, Kharat M, John JD, et al. Medicine. 2025.
6. Thrombocytopenia: Evaluation and Management. — Gauer RL, Whitaker DJ. American Family Physician. 2022.
7. Drug-Induced Immune Thrombocytopenia. — Aster RH, Bougie DW. The New England Journal of Medicine. 2007.
8. Updated Guidelines for Immune Thrombocytopenic Purpura: Expanded Management Options. — DeSouza S, Angelini D. Cleveland Clinic Journal of Medicine. 2021.
9. Immune Thrombotic Thrombocytopenic Purpura. — Pishko AM, Li A, Cuker A. The Journal of the American Medical Association. 2025.
10. Guideline on the Emergency Management of Critical Bleeding in Patients With Immune Thrombocytopenia. — Chowdhury SR, Sirotich E, Guyatt GH, et al. Blood Advances. 2026.
11. FDA Orange Book. — FDA Orange Book. 2026.
12. American Society of Hematology 2019 Guidelines for Immune Thrombocytopenia. — Neunert C, Terrell DR, Arnold DM, et al. Blood Advances. 2019.
13. ACOG Practice Bulletin No. 207: Thrombocytopenia in Pregnancy. — Committee on Practice Bulletins—Obstetrics Obstetrics and Gynecology. 2019.
14. Reference Guide for the Diagnosis of Adult Primary Immune Thrombocytopenia, 2023 Edition. — Kashiwagi H, Kuwana M, Murata M, et al. International Journal of Hematology. 2024.
15. Eltrombopag for Newly Diagnosed Pediatric Immune Thrombocytopenia Requiring Treatment. — Shimano KA, Grimes AB, Kaicker S, et al. The Journal of the American Medical Association. 2025.
16. Autoimmune thrombocytopenia: Current treatment options in adults with a focus on novel drugs. — Witkowski M, Witkowska M, Robak T. European Journal of Haematology. 2019.